Genmab A (GMAB) Change in Account Payables (2023 - 2026)

Genmab A (GMAB) has reported Change in Account Payables for 4 consecutive years, with -$8.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables fell 115.69% year-over-year to -$8.0 million; the trailing twelve-month figure through Jun 2026 stood at -$117.0 million (down 160.0% YoY), and the FY2025 full-year result was $400.0 million, up 227.87% from the prior year.
• Change in Account Payables grew to -$8.0 million in Q2 2026 per GMAB's latest filing, from -$261.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $109.0 million in Q2 2024 and bottomed at -$535.0 million in Q4 2023.
• Historically, Change in Account Payables has averaged -$53.2 million across 4 years, with a median of $29.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables grew 24.69% in 2025, then slumped 467.39% in 2026.
• Over 4 years, Change in Account Payables stood at -$535.0 million in 2023, then surged by 115.14% to $81.0 million in 2024, then rose by 24.69% to $101.0 million in 2025, then tumbled by 107.92% to -$8.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$8.0 million, -$261.0 million, and $101.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.